Zentalis Pharmaceuticals (ZNTL) Free Cash Flow (2019 - 2026)

Zentalis Pharmaceuticals' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$33.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 1.08% year-over-year to -$33.0 million; the TTM figure through Mar 2026 stood at -$125.6 million (up 17.21% YoY), while the FY2025 annual figure was -$125.2 million, up 26.79% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$33.0 million, down from -$30.9 million in the prior quarter.
• The five-year high for Free Cash Flow was -$27.0 million in Q3 2025, with the low at -$79.6 million in Q2 2023.
• The 5-year median for Free Cash Flow is -$38.8 million (2023), against an average of -$41.4 million.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow slumped 85.57% in 2023, then surged 55.62% in 2024.
• Zentalis Pharmaceuticals' Free Cash Flow stood at -$37.5 million in 2022, then slipped by 8.76% to -$40.8 million in 2023, then increased by 2.62% to -$39.7 million in 2024, then rose by 22.07% to -$30.9 million in 2025, then retreated by 6.63% to -$33.0 million in 2026.
• Business Quant data shows ZNTL's Free Cash Flow at -$33.0 million in Q1 2026, -$30.9 million in Q4 2025, and -$27.0 million in Q3 2025.